CUA 2017: Outcomes of an Aggressive Biopsy Strategy in Young Men with Prostate-Specific Antigen Between 0.5 and 2.5
Toronto, Ontario (UroToday.com) At the prostate cancer podium session at the 2017 CUA annual meeting, Dr. Hanan Goldberg and colleagues presented their work assessing outcomes of an aggressive prostate biopsy strategy among young men with a PSA between 0.5 and 2.5 ng/mL. With widespread PSA screening, prostate cancer detection rates have increased, particularly among young men (<50 years of age).
CUA 2017: Magnetic Resonance Imaging-Targeted vs. Systematic Biopsies in Men on Active Surveillance: Results of a Prospective, Randomized Canadian Urology Research Consortium Trial.
Toronto, Ontario (UroToday.com) Dr. Laurence Klotz presented the first report of a multicentre, prospective, randomized phase 3 trial (ASIST) attempting to determine if multiparametric magnetic resonance imaging (mpMRI) and targeted biopsy can improve selection of patients eligible for active surveillance. The question of the study was to see whether mpMRI and targeted biopsy improved detection of clinically significant cancer compared to systematic biopsy. The primary outcome was the proportion of subjects whose biopsy was upgraded at their confirmatory biopsy to Gleason score 7 (3 + 4) or higher.
CUA 2017: Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer
Toronto, Ontario (UroToday.com) Prostate Cancer (PCa) is a highly heterogeneous disease, ranging from indolent to rapidly progressing life-threatening metastatic disease. There is a need for markers identifying patients at increased risk of harbouring aggressive forms of PCa. Dr. Alexandre Zlotta presented a study surveying the Kallikrein (KLK) region (KLK1-15) for single nucleotide polymorphisms (SNPs) associated with aggressive PCa (Gleason score ≥8) in 1858 PCa patients.
CUA 2017: Association Between Germline Genetic Variation and Progression in Men with Low-Risk Prostate Cancer on Active Surveillance
Toronto, Ontario (UroToday.com) Viranda Jayalath, a medical student from Princess Margaret Cancer Center in Toronto, Canada, elegantly presented his study assessing the association between germline genetic variation and progression in men with low risk prostate cancer (PC) on active surveillance (AS). AS is the preferred initial treatment strategy for men with localized, low-risk PC.
CUA 2017: Prostate-Specific Antigen Levels in Men Aged 60-70 and Development of Lethal Prostate Cancer Over 30 Years: Implications for Risk-Stratified Screening
Toronto, Ontario (UroToday.com) Dr. Mark Preston from Brigham and Women’s Hospital presented their group’s results of PSA levels in men 60-70 years of age and 30-year risk of developing lethal prostate cancer at the prostate cancer podium session at the 2017 CUA annual meeting. With a push over the past five years towards less detection and treatment of low grade prostate cancer, studies assessing unique screening algorithms to limit untoward screening are important.
CUA 2017: Defining a Cohort of Men Who May Not Require Repeat Prostate Biopsy Based on Negative Predictive Value of PCA3 and MRI Combined: The Double-Negative Effect
Toronto, Ontario (UroToday.com) At the prostate cancer podium session at the 2017 CUA meeting, Dr. Nathan Perlis from the University of Toronto presented early results of men with a negative prostate biopsy who then subsequently had a negative PCA3 biomarker test and negative multiparametric MRI (mpMRI) to assess if they require a repeat biopsy.
CUA 2017: Chemotherapy and Novel Hormones in “Low Volume” Hormone-Sensitive Metastatic Prostate Cancer
Toronto, Ontario (UroToday.com) Dr. Oliver Sartor from Tulane University provided a comprehensive talk today during the CUA-CUOG Multidisciplinary GU cancer meeting at the CUA 2017 annual meeting. According to Dr. Sartor, the definition of metastatic prostate cancer disease is imaging dependent, as CT and bone scan are limited to detecting 1cc lesions (or 1 billion cells). How do we improve detection of disease compared to CT and bone scan?